EVP, R&D and CSO · AbbVie Inc. · Common Stock, $0.01 par value
Side
A
Value
—
Shares
2,138
Price
—
Executed
Feb 18, 2026
Disclosed
Feb 20, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Feb 18 executedFeb 20, 2026 disclosed
ABBV · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · 4.4% of prior position
Filing timing0 / 15
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Thakkar Roopal filed this Form 4 reporting a grant or award of ABBV on Feb 18, 2026. It became public on Feb 20, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
EVP, R&D and CSO
Thakkar Roopalcik:0002004979
Issuer
AbbVie Inc.cik:0001551152
Revision history · 0
No field has changed since this record was first ingested.
